E
EXELIXIS INC
NASDAQ: EXEL (Exelixis, Inc.)
Last update: 3 hours ago39.15
0.60 (1.56%)
| Previous Close | 38.55 |
| Open | 38.52 |
| Volume | 1,952,857 |
| Avg. Volume (3M) | 2,586,204 |
| Market Cap | 10,789,113,856 |
| Price / Earnings (TTM) | 22.24 |
| Price / Earnings (Forward) | 17.51 |
| Price / Sales | 5.26 |
| Price / Book | 4.73 |
| 52 Weeks Range | |
| Earnings Date | 13 May 2025 |
| Profit Margin | 24.04% |
| Operating Margin (TTM) | 28.84% |
| Diluted EPS (TTM) | 1.76 |
| Quarterly Revenue Growth (YOY) | 18.20% |
| Quarterly Earnings Growth (YOY) | 63.50% |
| Total Debt/Equity (MRQ) | 9.62% |
| Current Ratio (MRQ) | 3.63 |
| Operating Cash Flow (TTM) | 699.97 M |
| Levered Free Cash Flow (TTM) | 464.22 M |
| Return on Assets (TTM) | 14.64% |
| Return on Equity (TTM) | 23.13% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Exelixis, Inc. | Bullish | Bullish |
AIStockmoo Score
0.6
| Analyst Consensus | -1.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.63 |
|
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 2.25% |
| % Held by Institutions | 94.25% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Farallon Capital Management Llc | 31 Dec 2024 | 23,439,500 |
| Fuller & Thaler Asset Management, Inc. | 31 Dec 2024 | 7,630,940 |
| Invesco Ltd. | 31 Dec 2024 | 3,975,241 |
| Aqr Capital Management Llc | 31 Dec 2024 | 3,967,005 |
| Nuveen Asset Management, Llc | 31 Dec 2024 | 3,499,915 |
| Charles Schwab Investment Management Inc | 31 Dec 2024 | 3,252,353 |
| Arrowstreet Capital, Limited Partnership | 31 Dec 2024 | 3,159,395 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 45.00 (Citigroup, 14.94%) | Buy |
| Median | 39.00 (-0.38%) | |
| Low | 29.00 (Stephens & Co., -25.93%) | Hold |
| 29.00 (Barclays, -25.93%) | Hold | |
| Average | 37.60 (-3.96%) | |
| Total | 6 Buy, 4 Hold | |
| Avg. Price @ Call | 34.55 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JMP Securities | 17 Apr 2025 | 41.00 (4.73%) | Buy | 36.19 |
| HC Wainwright & Co. | 27 Mar 2025 | 40.00 (2.17%) | Buy | 36.84 |
| 13 Feb 2025 | 40.00 (2.17%) | Buy | 34.49 | |
| RBC Capital | 13 Mar 2025 | 40.00 (2.17%) | Buy | 36.80 |
| Wells Fargo | 24 Feb 2025 | 36.00 (-8.05%) | Hold | 37.13 |
| Barclays | 13 Feb 2025 | 29.00 (-25.93%) | Hold | 34.49 |
| Citigroup | 12 Feb 2025 | 45.00 (14.94%) | Buy | 32.80 |
| Guggenheim | 12 Feb 2025 | 42.00 (7.28%) | Buy | 32.80 |
| Piper Sandler | 12 Feb 2025 | 38.00 (-2.94%) | Buy | 32.80 |
| Stephens & Co. | 12 Feb 2025 | 29.00 (-25.93%) | Hold | 32.80 |
| Stifel | 12 Feb 2025 | 36.00 (-8.05%) | Hold | 32.80 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |